Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04949295
Other study ID # 2021JN
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2021

Study information

Verified date April 2022
Source First Affiliated Hospital of Jinan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

We clinically observed that some hemodialysis patients had corneal epithelial dryness, shedding, edema, and persistent epithelial nonunion after ocular surgery, which seriously affected the effect of surgery, and it is necessary to study the ocular surface characteristics of hemodialysis patients. In this study, we examined the ocular surface and analyzed and investigated the characteristics of the ocular surface in hemodialysis patients to provide a basis for ocular surface intervention or treatment in hemodialysis patients before ocular surgery in clinical practice.


Description:

This study is a clinical case-control study. A total of 36 hemodialysis patients and 36 normal subjects were randomly selected from the Nephrology Department of the First Affiliated Hospital of Jinan University .All the subjects in the hemodialysis group (n = 36, 72 eyes) and the normal group (n = 36, 72 eyes) were investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 72 Years
Eligibility the hemodialysis group Inclusion Criteria: - Older than 18 - Hemodialysis patient - The subject understands the purpose of this clinical trial and agrees to sign an informed consent form. the hemodialysis group Exclusion Criteria: - Previous history of ocular trauma or surgery - History of wearing contact lenses - Can Not Stop the use of dry eye caused by drugs and other drugs may directly affect the stability of tear film tears - Eyelid abnormalities (such as eyelid insufficiency, entropion and ECTROPION, tumor, severe trichiasis) - There have been peritoneal dialysis, kidney transplant surgery patients. the normal group Inclusion Criteria: - Older than 18 - Healthy people do not have other systemic diseases, such as diabetes and hypertension - The subject understands the purpose of this clinical trial and agrees to sign an informed consent form. the normal group Exclusion Criteria: - Previous history of ocular trauma or surgery - History of wearing contact lenses - Can Not Stop the use of dry eye caused by drugs and other drugs may directly affect the stability of tear film tears.

Study Design


Intervention

Device:
ocular surface analyzer
Using ocular surface analyzer for Inspection

Locations

Country Name City State
China The First Affiliated Hospital of Jinan University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
XiaoYong Liu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Non-invasive tear meniscus height Maximum and minimum of Non-invasive tear meniscus height in millimetre,higher scores mean a better outcome. 1year
Primary first tear film break-up time Maximum and minimum of first tear film break-up time in Seconds,higher scores mean a better outcome. 1year
Primary average tear film break-up time Maximum and minimum of average tear film break-up time in Seconds,higher scores mean a better outcome. 1year
Primary dry eye severity grade Maximum and minimum of dry eye severity grade,higher scores mean a worse outcome. 1year
Primary tear film lipid layer analysis (distribution and color) Maximum and minimum of tear film lipid layer analysis (distribution and color),higher scores mean a better outcome. 1year
Primary tear film lipid layer thickness grade Maximum and minimum of tear film lipid layer thickness grade,higher scores mean a better outcome. 1year
Primary meibomian gland opening blocking site Maximum and minimum of meibomian gland opening blocking site,higher scores mean a worse outcome. 1year
Primary meibomian gland opening blocking analysis Maximum and minimum of meibomian gland opening blocking analysis,higher scores mean a worse outcome. 1year
Primary meibomian gland opening secretion oil character score Maximum and minimum of meibomian gland opening secretion oil character score,higher scores mean a worse outcome. 1year
Primary eye redness index analysis (conjunctiva, ciliary shape) Maximum and minimum of eye redness index analysis (conjunctiva, ciliary shape),higher scores mean a worse outcome. 1year
Primary meibomian gland absence area score Maximum and minimum of meibomian gland absence area score,higher scores mean a worse outcome. 1year
See also
  Status Clinical Trial Phase
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A